// App-Quantinova.ai

FRI0272 : SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS OVER LONG TERM: UPDATED POOLED SAFETY ANALYSES

Researchers

Presenter

  • A. Deodhar

Principal Investigators

  • I. Mcinnes

  • X. Baraliakos

  • K. Reich

  • A. B. Gottlieb

  • M. Lebwohl

  • S. Schreiber

  • W. Bao

  • K. Marfo

  • H. Richards

  • L. Pricop

  • A. Shete

  • J. Safi

  • P. J. Mease

Medical Centers

  • Oregon Health & Science University, Portland, United States of America

  • University of Glasgow, Glasgow, United Kingdom

  • Ruhr-University Bochum, Bochum, Germany

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Skinflammation® Center, Hamburg, Germany

  • Icahn School of Medicine at Mount Sinai Hospital - New York - United States of America

  • St. Barnabas Hospital, New York, United States of America

  • University Hospital Schleswig-Holstein, Lubeck, Germany

  • Novartis Pharmaceuticals Corporation, US HEOR, East Hanover, United States of America

  • Novartis AG, Basel, Switzerland

Locations

  • United States

  • United Kingdom

  • Germany

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

  • Psoriatic arthritis

  • Inflammatory Arthritis

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • IV

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved